2-Amino-2-deoxy-O³-<β-D-glucopyranuronosyl>-D-glucose | 112464-83-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Amino-2-deoxy-O³-<β-D-glucopyranuronosyl>-D-glucose
• 英文别名: 2-Amino-2-deoxy-3-O-β-D-glucopyranuronosyl-D-glucopyranose；GlcA(b1-3)a-GlcN；(2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-amino-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
• CAS: 112464-83-2
• 化学式: C₁₂H₂₁NO₁₁
• 分子量: 355.299
• InChiKey: MMVCEIQLWBYBJB-OYQIKJLFSA-N

物化性质

• 沸点：
  747.5±60.0 °C(predicted)
• 密度：
  1.80±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -6.5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  212
• 氢给体数：
  8
• 氢受体数：
  12

文献信息

• Bioadhesive pharmaceutical compositions
  申请人：——

  公开号：US20040142880A1

  公开（公告）日：2004-07-22

  Disclosed are compounds having the formula 1 wherein R 2 is hydrogen, a monomeric glycoside or an oligomeric glycoside, R 3 is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula 2 R is a lower alkylene, R′ is selected from the group consisting of moieties having the formula 3 where X=0 or 1, Y=0 or 1, R 1 is hydrogen or a pharmacologically active drug residue, R 8 a pharmacologically active drug residue, R 4 , R 5 , and R 6 are independently hydrogen, alkyl, aryl, aralkyl, and cycloalkyl or together form a nitrogen-containing ring, and R 7 is hydroxyl or hydroxyalkyl.

  揭示了具有以下化学式1的化合物，其中R2是氢、单体糖苷或寡聚糖苷，R3是氢、单体糖苷、寡聚糖苷或具有化学式2的基团。R是较低的烷基，R′从具有化学式3的基团中选择，其中X=0或1，Y=0或1，R1是氢或药理活性药物残基，R8是药理活性药物残基，R4、R5和R6独立地是氢、烷基、芳基、芳基烷基和环烷基，或者一起形成含氮环，R7是羟基或羟基烷基。
• 1,3,5-Triazines for Treatment of Viral Diseases
  申请人：Daifuku Richard

  公开号：US20070207973A1

  公开（公告）日：2007-09-06

  The present invention provides compounds and methods for treatment of viral diseases and cancer.

  本发明提供了用于治疗病毒性疾病和癌症的化合物和方法。
• Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof
  申请人：Holick F Michael

  公开号：US20050153928A1

  公开（公告）日：2005-07-14

  Disclosed are conjugates comprising a central nervous system-active drug linked through an amide bond to a glucuronic acid or glucosamine moiety, and uses thereof, e.g., for treating or ameliorating central nervous system diseases or disorders.

  本发明涉及一种共轭物，其包括通过酰胺键连接到葡萄糖醛酸或葡萄糖胺基团的中枢神经系统活性药物，以及其用途，例如用于治疗或改善中枢神经系统疾病或障碍。
• 1,3,5-Triazines for treatment of viral diseases
  申请人：Koronis Pharmaceuticals, Inc.

  公开号：US20040127436A1

  公开（公告）日：2004-07-01

  The present invention provides compounds and methods for treatment of viral diseases and cancer.

  本发明提供了用于治疗病毒性疾病和癌症的化合物和方法。
• Novel methods of imaging and treatment with targeted compositions
  申请人：——

  公开号：US20030157025A1

  公开（公告）日：2003-08-21

  Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

  新型超声波方法包括向患者施加含有脂质、蛋白质或聚合物的气囊组成的有针对性的气囊组合物，该气囊包含一种气体，并与一个靶向配体结合，然后使用超声波扫描患者。扫描可能包括将患者暴露于第一种超声波能量，然后使用第二种超声波能量对患者进行询问。靶向配体首选靶向组织、细胞或受体，包括心肌细胞、内皮细胞、上皮细胞、肿瘤细胞和糖蛋白GPIIbIIIa受体。该方法可用于检测血栓、旧血栓或回声增强、低浓度气囊和靶向组织、细胞或受体的气囊。